These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

242 related items for PubMed ID: 21572154

  • 1. Does anti-tumor necrosis factor-α therapy affect risk of serious infection and cancer in patients with rheumatoid arthritis?: a review of longterm data.
    Keystone EC.
    J Rheumatol; 2011 Aug; 38(8):1552-62. PubMed ID: 21572154
    [Abstract] [Full Text] [Related]

  • 2. Incidence and risk factors for serious infection in patients with rheumatoid arthritis treated with tumor necrosis factor inhibitors: a report from the Registry of Japanese Rheumatoid Arthritis Patients for Longterm Safety.
    Komano Y, Tanaka M, Nanki T, Koike R, Sakai R, Kameda H, Nakajima A, Saito K, Takeno M, Atsumi T, Tohma S, Ito S, Tamura N, Fujii T, Sawada T, Ida H, Hashiramoto A, Koike T, Ishigatsubo Y, Eguchi K, Tanaka Y, Takeuchi T, Miyasaka N, Harigai M, REAL Study Group.
    J Rheumatol; 2011 Jul; 38(7):1258-64. PubMed ID: 21498482
    [Abstract] [Full Text] [Related]

  • 3. The safety of anti-tumour necrosis factor treatments in rheumatoid arthritis: meta and exposure-adjusted pooled analyses of serious adverse events.
    Leombruno JP, Einarson TR, Keystone EC.
    Ann Rheum Dis; 2009 Jul; 68(7):1136-45. PubMed ID: 18753157
    [Abstract] [Full Text] [Related]

  • 4. Anti-TNF therapy: safety aspects of taking the risk.
    Rosenblum H, Amital H.
    Autoimmun Rev; 2011 Jul; 10(9):563-8. PubMed ID: 21570495
    [Abstract] [Full Text] [Related]

  • 5. Does cancer that occurs during or after anti-tumor necrosis factor therapy have a worse prognosis? A national assessment of overall and site-specific cancer survival in rheumatoid arthritis patients treated with biologic agents.
    Raaschou P, Simard JF, Neovius M, Askling J, Anti-Rheumatic Therapy in Sweden Study Group.
    Arthritis Rheum; 2011 Jul; 63(7):1812-22. PubMed ID: 21305513
    [Abstract] [Full Text] [Related]

  • 6. Tumor necrosis factor therapy and the risk of serious infection and malignancy in patients with early rheumatoid arthritis: a meta-analysis of randomized controlled trials.
    Thompson AE, Rieder SW, Pope JE.
    Arthritis Rheum; 2011 Jun; 63(6):1479-85. PubMed ID: 21360522
    [Abstract] [Full Text] [Related]

  • 7. TNF antagonist safety in rheumatoid arthritis: updated evidence from observational registries.
    Nasir A, Greenberg JD.
    Bull NYU Hosp Jt Dis; 2007 Jun; 65(3):178-81. PubMed ID: 17922666
    [Abstract] [Full Text] [Related]

  • 8. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-α biologics by rheumatoid arthritis patients.
    Thyagarajan V, Norman H, Alexander KA, Napalkov P, Enger C.
    Semin Arthritis Rheum; 2012 Dec; 42(3):223-33. PubMed ID: 22748510
    [Abstract] [Full Text] [Related]

  • 9. TNF-alpha antagonism and cancer risk in rheumatoid arthritis: is continued vigilance warranted?
    Park HJ, Ranganathan P.
    Discov Med; 2012 Mar; 13(70):229-34. PubMed ID: 22463799
    [Abstract] [Full Text] [Related]

  • 10. Lymphoma in rheumatoid arthritis: the effect of methotrexate and anti-tumor necrosis factor therapy in 18,572 patients.
    Wolfe F, Michaud K.
    Arthritis Rheum; 2004 Jun; 50(6):1740-51. PubMed ID: 15188349
    [Abstract] [Full Text] [Related]

  • 11. The infectious profiles of anti-tumor necrosis factor agents in a Thai population: a retrospective study a the university-based hospital.
    Suwannalai P, Auethavekiat P, Udomsubpayakul U, Janvitayanujit S.
    Int J Rheum Dis; 2009 Jul; 12(2):118-24. PubMed ID: 20374328
    [Abstract] [Full Text] [Related]

  • 12. Adalimumab: new preparation. Rheumatoid arthritis: no therapeutic advance.
    Prescrire Int; 2004 Oct; 13(73):171-5. PubMed ID: 15499697
    [Abstract] [Full Text] [Related]

  • 13. Infliximab treatment of rheumatoid arthritis and Crohn's disease.
    Nahar IK, Shojania K, Marra CA, Alamgir AH, Anis AH.
    Ann Pharmacother; 2003 Sep; 37(9):1256-65. PubMed ID: 12921510
    [Abstract] [Full Text] [Related]

  • 14. Toxoplasmic chorioretinitis and antitumor necrosis factor treatment in rheumatoid arthritis.
    Lassoued S, Zabraniecki L, Marin F, Billey T.
    Semin Arthritis Rheum; 2007 Feb; 36(4):262-3. PubMed ID: 17067660
    [Abstract] [Full Text] [Related]

  • 15. Comparative overview of safety of the biologics in rheumatoid arthritis.
    Khraishi M.
    J Rheumatol Suppl; 2009 Jun; 82():25-32. PubMed ID: 19509327
    [Abstract] [Full Text] [Related]

  • 16. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers.
    Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS, Kim TH, Jun JB, Yoo DH, Lee JT, Bae SC.
    J Rheumatol; 2007 Apr; 34(4):706-11. PubMed ID: 17309133
    [Abstract] [Full Text] [Related]

  • 17. [Meta analysis of infection risks of anti-TNF-α treatment in rheumatoid arthritis].
    Xie X, Chen J, Peng Y, Gao J, Tian J, Ling G, Du J, Mao N, Wu P, Li F.
    Zhong Nan Da Xue Xue Bao Yi Xue Ban; 2013 Jul; 38(7):722-36. PubMed ID: 23908082
    [Abstract] [Full Text] [Related]

  • 18. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden.
    Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, Geborek P, Jacobsson LT, Lindblad S, Lysholm J, Rantapää-Dahlqvist S, Saxne T, Romanus V, Klareskog L, Feltelius N.
    Arthritis Rheum; 2005 Jul; 52(7):1986-92. PubMed ID: 15986370
    [Abstract] [Full Text] [Related]

  • 19. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    Ang HT, Helfgott S.
    J Rheumatol; 2003 Nov; 30(11):2315-8. PubMed ID: 14677170
    [Abstract] [Full Text] [Related]

  • 20. Anti-tumor necrosis factor therapy: 6 year experience of a single center in northern Israel and possible impact of health policy on results.
    Braun-Moscovici Y, Markovits D, Rozin A, Toledano K, Nahir AM, Balbir-Gurman A.
    Isr Med Assoc J; 2008 Apr; 10(4):277-81. PubMed ID: 18548981
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.